PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

MIG sells portfolio company Hemovent to MicroPort

MIG Capital AG has sold portfolio company, Hemovent to MicroPort Surgical BV, a subsidiary of Shanghai-based MicroPort Scientific Corporation, (MicroPort) for a total purchase price of up to EUR123 million. 

Split between two funds MIG holds more than 27 per cent of Hemovent.

Hemovent develops and manufactures Extra Corporal Lung Support (ECLS) systems for the intensive care setting. Based on the classic heart-lung machine, this technology takes over the heart and/or lung function of a patient for up to several weeks. Hemovent wants to significantly expand the application range of these life-saving systems, particularly for emergency use. The proprietary MOBYBOX is an extremely mobile and lightweight machine in a “handbag” design and is considerably simpler to operate than current systems on the market. MOBYBOX can thus help save human lives in mobile emergency applications.

“In just five years, Hemovent has succeeded in developing the MOBYBOX, a mobile ECLS device that is ready for the market,” says Matthias Guth, Venture Partner of MIG Capital AG. “This is an extraordinary achievement and places the company in a unique position in the international market for heart and lung support. We are very proud to have been an important part of this success story as lead investor. Furthermore, the timing of this deal is excellent for the sale to a strategic partner. As part of a global medical technology group, Hemovent can take its business model and the commercialisation of devices to a new level.”

The transaction has received all the necessary regulatory approvals and is expected to close in the fourth quarter of 2021.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured